Low-Dose Naltrexone: Compounded vs Branded Comparison

The Core Difference Is the Dosage Form, Not a Different Drug

FDA-approved oral naltrexone tablets contain 50 mg of naltrexone hydrochloride. The current label describes use for alcohol dependence and opioid blockade; it does not include fibromyalgia, autoimmune disease, chronic pain, or a low-dose indication 1.

"Low-dose naltrexone" is a clinical shorthand, not an FDA-defined product. Published studies have commonly evaluated oral doses around 4.5 mg, with some trials using other low doses. A compounding pharmacy can prepare a prescribed capsule or liquid at one of those individualized strengths. A clinician may also discuss whether an approved tablet can appropriately be used, but a scored 50 mg tablet is designed to split into halves—not into eleven equal 4.5 mg portions. Patients should not improvise a dilution or alter tablets without instructions from a pharmacist or prescriber.

Extended-release injectable naltrexone is a separate formulation intended to maintain opioid blockade over weeks. Its dose and release profile do not make it interchangeable with oral LDN.

Compounded LDN vs FDA-Approved Naltrexone

FDA explains that compounded drugs can meet an important need when an approved drug is not medically appropriate for a particular patient. It also emphasizes that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality 2. This is the most important regulatory and quality distinction; it should not be replaced with claims that every compounded capsule has the same testing as an approved product.

Does Compounded LDN Work Better?

No comparative trial has shown that a compounded capsule, compounded liquid, or carefully prepared dose from a commercial tablet produces better clinical outcomes than another oral form at the same delivered dose. Most LDN studies were designed to compare naltrexone with placebo, not to compare pharmacy formulations.

That means the defensible benefit of compounding is practical: it can deliver a prescribed low strength, avoid a particular inactive ingredient when medically necessary, or provide a liquid for someone who cannot use a tablet or capsule. Claims that a particular filler improves absorption, that calcium carbonate reduces exposure by a fixed percentage, or that one LDN vehicle is clinically superior require direct formulation data that are not currently available.

What the Clinical Evidence Actually Shows

Fibromyalgia

The evidence is mixed. A 2009 pilot included 10 women and found a greater than 30% symptom reduction over placebo with 4.5 mg naltrexone, but its very small sample and crossover design limit certainty 3. A later small crossover trial also reported a pain signal 4.

Larger and more recent randomized evidence has been less encouraging. A 2023 randomized crossover study of 58 patients did not find clinically relevant analgesic efficacy for 4.5 mg compared with placebo 5. A 2024 randomized trial tested 6 mg against placebo in women with fibromyalgia 6. Recent meta-analyses have reached different conclusions because they include a small number of heterogeneous trials. The fair summary is that LDN remains investigational for fibromyalgia; it is not an established replacement for guideline-supported care.

Crohn's Disease

A randomized placebo-controlled study enrolled 40 adults with active Crohn's disease and tested oral 4.5 mg naltrexone for 12 weeks. It reported more clinical response in the naltrexone group 7. A Cochrane review found only two small randomized studies totaling 46 participants and concluded that the evidence was insufficient for firm conclusions 8. LDN should not be presented as a substitute for therapies with established evidence for inducing or maintaining remission.

Multiple Sclerosis and Other Conditions

Small trials have evaluated quality-of-life or symptom outcomes in multiple sclerosis, but they have not established LDN as a disease-modifying therapy 9. Evidence from one condition cannot be generalized to thyroid disease, Long COVID, cancer, or a broad category of "autoimmune conditions."

Safety Questions Matter More Than the Formulation Debate

Naltrexone is an opioid antagonist. The current tablet label recommends an opioid-free interval of at least 7 to 10 days for people previously dependent on short-acting opioids and warns that people transitioning from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as two weeks 1. The appropriate interval is individualized; it is not a do-it-yourself washout schedule.

Before considering LDN, a prescriber needs to know about:

• opioid pain medicines, tramadol, buprenorphine, methadone, and recent illicit opioid exposure;
• opioid-containing cough or diarrhea medicines;
• an anticipated operation, dental procedure, or injury plan that may require opioid analgesia;
• acute hepatitis, significant liver disease, or prior abnormal liver tests;
• pregnancy, breastfeeding, and all other prescription and nonprescription medicines.

Trying to override naltrexone's blockade with high opioid doses can cause fatal overdose. After naltrexone is stopped, reduced opioid tolerance can also increase overdose risk. A patient who develops severe abdominal pain, dark urine, yellowing of the skin or eyes, or symptoms of precipitated withdrawal needs prompt medical evaluation.

How to Compare Compounding Pharmacies

The correct questions are verifiable and patient-specific:

1. Is the pharmacy licensed in the state where the patient will receive the prescription?
2. Who is the dispensing pharmacy, and will its name appear before payment?
3. What exact strength, dosage form, and inactive ingredients will be dispensed?
4. What storage instructions and beyond-use date apply to this preparation?
5. How should missed doses, planned procedures, or a new need for pain treatment be handled?
6. Whom should the patient contact about a suspected quality problem or adverse event?

Accreditation can add information, but it should not be described as FDA approval or as proof that every batch has undergone the same testing as an approved drug. FDA notes that state boards generally oversee traditional state-licensed pharmacies, while registered outsourcing facilities have a different federal framework 2.

A Practical Decision Framework

Choose the clinical question first. What condition and outcome are being treated, and what better-established options have been considered?

Confirm that naltrexone is compatible with the medication plan. Any current or likely opioid need can change the risk-benefit decision.

Then choose the dosage form. If a prescriber selects a low individualized dose that is not commercially available, compounding may be the practical route. If the approved product can appropriately meet the need, FDA generally recommends using an approved drug.

Set an evaluation point. Because efficacy is uncertain and varies by condition, the prescriber and patient should define what improvement would count, how it will be measured, and when continued treatment will be reconsidered.

Bottom Line

Compounded LDN offers dose and formulation flexibility. It is not a branded competitor with demonstrated superior efficacy, and it is not an FDA-approved treatment for fibromyalgia, Crohn's disease, multiple sclerosis, or autoimmune disease. The choice should be based on a specific medical need, the limited evidence for the condition, the quality and transparency of the dispensing pharmacy, and—above all—safe management of opioid interactions.